Compass Therapeutics (CMPX) Revenue & Revenue Breakdown
Compass Therapeutics Revenue Highlights
Compass Therapeutics Revenue by Period
Compass Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Compass Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Compass Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.84M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | - |
Compass Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Compass Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IDYA | IDEAYA Biosciences | $23.39M | - |
| IVA | Inventiva | $17.50M | $15.58M |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| KRON | Kronos Bio | $6.29M | $2.69M |
| PRTC | PureTech Health | $3.33M | $178.57K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| AVTE | Aerovate Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| VIGL | Vigil Neuroscience | - | - |
| NVCT | Nuvectis Pharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| ELVN | Enliven Therapeutics | - | - |
| CMPX | Compass Therapeutics | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
CMPX Revenue FAQ
What is Compass Therapeutics’s yearly revenue?
Compass Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. CMPX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Compass Therapeutics’s quarterly revenue?
Compass Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.84M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). CMPX's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Compass Therapeutics’s revenue growth rate?
Compass Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.